JUBILEE CLINICAL RESEARCH, INC.
EXCELLENCE · WELLNESS · PHILANTHROPY
NASH (NON-ALCOHOLIC STEATOHEPATITIS)
WHAT IS FATTY LIVER DISEASE?
NASH (Non-Alcoholic SteatoHepatitis) is the medical term for this devastating disease which not too many people know about yet is on the rise affecting more than 25 percent of the U.S. population. NASH is caused when too much fat is built up in the liver causing inflammation and damage. It is a result of a condition called nonalcoholic fatty liver disease, which can get worse and cause scarring of the liver, leading to cirrhosis. It is a silent killer, usually without any symptoms, and the fastest-growing reason for liver transplants in America, especially in women and the elderly. NASH tends to affect people who are overweight, have diabetes, under-active thyroid (hypothyroidism), high blood pressure, high cholesterol, or have high triglycerides. However, some people have NASH even if they do not have any risk factors, and patients may remain unaware of their liver condition, which can progress to more serious disease. Once there is an overabundance of excess fat accumulation in the liver, more complications arise such as chronic inflammation and a higher risk of death from cardiovascular disease. NASH is one of the leading causes of cirrhosis in adults in the United States.
It is important to get screened for fatty liver with FibroScan especially if you have any one of the risk factors including diabetes, obesity, high cholesterol, or high blood pressure. In my opinion, FibroScanshould be part of annual physical check-ups for people with these risk factors. We offer it for free without any physician referral. Currently, there are no FDA-approved prescribed medications to treat NASH. However, it is FDA-approved through clinical trials. We offer this treatment without charge with compensation for time and travel. Visit our website to sign up for an appointment today.
NASH may lead to cirrhosis of the liver, it is important to get an early diagnosis and aim for the prevention of
NAFLD/NASH with Fibroscan screening, as treatment, is available through clinical trials only.
Visit our website for eligibility to sign up for this treatment without charge, and compensation for time and travel.
Jubilee Clinical Research, Inc. (JCR)was founded in 2017 by Elliot Shin, MS, MD, CPI, a board-certified family physician. The mission of JCR is to provide research excellence to the scientific community, promote wellness among patients and colleagues, and contribute significantly to philanthropy. With experienced investigators and staff, JCR provides invaluable clinical research excellence in diverse indications ranging from new diabetic therapeutics to the latest migraine treatments. Our vision is to use our resources wisely to eliminate poverty and suffering locally and worldwide.